Activin and Inhibin

Pipofezine(Azafen or Azaphen) is a potent inhibitor of the reuptake of serotonin.IC50 Value:Target: SSRIsPipofezine is a tricyclic antidepressant (TCA) approved in Russia for the treatment ofdepression.Form:Solid.

Pipofezine(Azafen or Azaphen) is a potent inhibitor of the reuptake of serotonin.IC50 Value:Target: SSRIsPipofezine is a tricyclic antidepressant (TCA) approved in Russia for the treatment ofdepression.

AZD-6280 is a selective GABAA(α2/3) receptor modulator, used for treatment of generalized anxiety disorder.Form:Solid.

AZD-6280 is a selective GABAA(α2/3) receptor modulator, used for treatment of generalized anxiety disorder.Form:Solid.

AZD-6280 is a selective GABAA(α2/3) receptor modulator, used for treatment of generalized anxiety disorder.Form:Solid.

AZD-6280 is a selective GABAA(α2/3) receptor modulator, used for treatment of generalized anxiety disorder.

AZD-9574 is a potent and brain penetrant PARP1 inhibitor and shows &gt:8000-fold selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. AZD-9574 is an anti-cancer agent and

AZD-9574 is a potent and brain penetrant PARP1 inhibitor and shows &gt:8000-fold selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. AZD-9574 is an anti-cancer agent and

AZD-9574 is a potent and brain penetrant PARP1 inhibitor and shows &gt:8000-fold selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. AZD-9574 is an anti-cancer agent and

AZD-9574 is a potent and brain penetrant PARP1 inhibitor and shows &gt:8000-fold selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. AZD-9574 is an anti-cancer agent and

AZD0095 is a selective and orally active MCT4 inhibitor ( IC 50 : 1.3 nM). AZD0095 effectively inhibits the tumor growth in NCI-H358 xenograft in combination with Cediranib ( HY-10205 )In VitroAZD0095 (0-50 µM) inhibits cell proliferation in

AZD0095 is a selective and orally active MCT4 inhibitor ( IC 50 : 1.3 nM). AZD0095 effectively inhibits the tumor growth in NCI-H358 xenograft in combination with Cediranib ( HY-10205 )In VitroAZD0095 (0-50 µM) inhibits cell proliferation in